McMinn Rachel's Form 4 filing
Neurogene Inc.NGNE · filed Mar 30, 2026
- Accession no.
- 0001606302-26-000005
- Filed
- Mar 30, 2026
- Trade date
- Mar 26, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $74.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McMinn RachelCIK 0001606302 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Common Stock | SSaleDisposed | −3,352 | $22.07 | −$73,978.64 | 1,344,307 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.